Your browser doesn't support javascript.
loading
The age again in the eye of the COVID-19 storm: evidence-based decision making.
Martín, María C; Jurado, Aurora; Abad-Molina, Cristina; Orduña, Antonio; Yarce, Oscar; Navas, Ana M; Cunill, Vanesa; Escobar, Danilo; Boix, Francisco; Burillo-Sanz, Sergio; Vegas-Sánchez, María C; Jiménez-de Las Pozas, Yesenia; Melero, Josefa; Aguilar, Marta; Sobieschi, Oana Irina; López-Hoyos, Marcos; Ocejo-Vinyals, Gonzalo; San Segundo, David; Almeida, Delia; Medina, Silvia; Fernández, Luis; Vergara, Esther; Quirant, Bibiana; Martínez-Cáceres, Eva; Boiges, Marc; Alonso, Marta; Esparcia-Pinedo, Laura; López-Sanz, Celia; Muñoz-Vico, Javier; López-Palmero, Serafín; Trujillo, Antonio; Álvarez, Paula; Prada, Álvaro; Monzón, David; Ontañón, Jesús; Marco, Francisco M; Mora, Sergio; Rojo, Ricardo; González-Martínez, Gema; Martínez-Saavedra, María T; Gil-Herrera, Juana; Cantenys-Molina, Sergi; Hernández, Manuel; Perurena-Prieto, Janire; Rodríguez-Bayona, Beatriz; Martínez, Alba; Ocaña, Esther; Molina, Juan.
Afiliação
  • Martín MC; Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain.
  • Jurado A; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain. aurora.jurado.sspa@juntadeandalucia.es.
  • Abad-Molina C; Department of Microbiology and Immunology, Hospital Clínico Universitario, Valladolid, Spain.
  • Orduña A; Department of Microbiology and Immunology, Hospital Clínico Universitario, Valladolid, Spain.
  • Yarce O; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain.
  • Navas AM; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain.
  • Cunill V; Department of Immunology, Hospital Universitario Son Espases-Human Immunopathology Research Laboratory, Institut d'Investigació Sanitària de les Illes Balears (IdISBa), Palma de Mallorca, Spain.
  • Escobar D; Department of Immunology, Hospital Universitario Son Espases-Human Immunopathology Research Laboratory, Institut d'Investigació Sanitària de les Illes Balears (IdISBa), Palma de Mallorca, Spain.
  • Boix F; Department of Immunology, Hospital Clínico Universitario, Salamanca, Spain.
  • Burillo-Sanz S; Department of Immunology, Hospital Clínico Universitario, Salamanca, Spain.
  • Vegas-Sánchez MC; Department of Immunology, Fundación Jiménez Díaz, Madrid, Spain.
  • Jiménez-de Las Pozas Y; Department of Immunology, Fundación Jiménez Díaz, Madrid, Spain.
  • Melero J; Department of Immunology, Hospital Universitario de Badajoz, Badajoz, Spain.
  • Aguilar M; Department of Immunology, Hospital Universitario de Badajoz, Badajoz, Spain.
  • Sobieschi OI; Department of Immunology, Hospital Universitario de Badajoz, Badajoz, Spain.
  • López-Hoyos M; Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Ocejo-Vinyals G; Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • San Segundo D; Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Almeida D; Laboratory of Immunology, Complejo Hospitalario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.
  • Medina S; Laboratory of Immunology, Complejo Hospitalario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.
  • Fernández L; Laboratoy of Immunology and Genetics, Hospital San Pedro de Alcántara, Cáceres, Spain.
  • Vergara E; Laboratoy of Immunology and Genetics, Hospital San Pedro de Alcántara, Cáceres, Spain.
  • Quirant B; Department of Immunology, Hospital Germans Trias i Pujols, Barcelona, Spain.
  • Martínez-Cáceres E; Department of Immunology, Hospital Germans Trias i Pujols, Barcelona, Spain.
  • Boiges M; Department of Immunology, Hospital Germans Trias i Pujols, Barcelona, Spain.
  • Alonso M; Department of Immunology, Hospital de Cruces, Baracaldo, Spain.
  • Esparcia-Pinedo L; Department of Immunology, Hospital Universitario La Princesa, Madrid, Spain.
  • López-Sanz C; Department of Immunology, Hospital Universitario La Princesa, Madrid, Spain.
  • Muñoz-Vico J; Department of Immunology, Hospital Torrecárdenas, Almería, Spain.
  • López-Palmero S; Department of Immunology, Hospital Torrecárdenas, Almería, Spain.
  • Trujillo A; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain.
  • Álvarez P; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain.
  • Prada Á; Department of Immunology, Hospital de Donostia, San Sebastián, Spain.
  • Monzón D; Department of Immunology, Hospital de Donostia, San Sebastián, Spain.
  • Ontañón J; Unit of Immunology, Hospital General Universitario, Albacete, Spain.
  • Marco FM; Laboratory Unit, Hospital General, Alicante, Spain.
  • Mora S; Laboratory Unit, Hospital General, Alicante, Spain.
  • Rojo R; Department of Immunology, Complejo Hospitalario, La Coruña, Spain.
  • González-Martínez G; Unit of Immunology, Hospital Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain.
  • Martínez-Saavedra MT; Unit of Immunology, Hospital Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain.
  • Gil-Herrera J; Department of Immunology, Hospital General Universitario e Instituto de Investigación Sanitaria, "Gregorio Marañón", Madrid, Spain.
  • Cantenys-Molina S; Department of Immunology, Hospital General Universitario e Instituto de Investigación Sanitaria, "Gregorio Marañón", Madrid, Spain.
  • Hernández M; Department of Immunology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Perurena-Prieto J; Department of Immunology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Rodríguez-Bayona B; Laboratory Unit, Hospital Juan Ramón Jiménez, Huelva, Spain.
  • Martínez A; Laboratory Unit, Complejo Hospitalario, Jaén, Spain.
  • Ocaña E; Laboratory Unit, Complejo Hospitalario, Jaén, Spain.
  • Molina J; Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), Avd. Menéndez Pidal s/n, 14004, Córdoba, Spain.
Immun Ageing ; 18(1): 24, 2021 May 20.
Article em En | MEDLINE | ID: mdl-34016150
BACKGROUND: One hundred fifty million contagions, more than 3 million deaths and little more than 1 year of COVID-19 have changed our lives and our health management systems forever. Ageing is known to be one of the significant determinants for COVID-19 severity. Two main reasons underlie this: immunosenescence and age correlation with main COVID-19 comorbidities such as hypertension or dyslipidaemia. This study has two aims. The first is to obtain cut-off points for laboratory parameters that can help us in clinical decision-making. The second one is to analyse the effect of pandemic lockdown on epidemiological, clinical, and laboratory parameters concerning the severity of the COVID-19. For these purposes, 257 of SARSCoV2 inpatients during pandemic confinement were included in this study. Moreover, 584 case records from a previously analysed series, were compared with the present study data. RESULTS: Concerning the characteristics of lockdown series, mild cases accounted for 14.4, 54.1% were moderate and 31.5%, severe. There were 32.5% of home contagions, 26.3% community transmissions, 22.5% nursing home contagions, and 8.8% corresponding to frontline worker contagions regarding epidemiological features. Age > 60 and male sex are hereby confirmed as severity determinants. Equally, higher severity was significantly associated with higher IL6, CRP, ferritin, LDH, and leukocyte counts, and a lower percentage of lymphocyte, CD4 and CD8 count. Comparing this cohort with a previous 584-cases series, mild cases were less than those analysed in the first moment of the pandemic and dyslipidaemia became more frequent than before. IL-6, CRP and LDH values above 69 pg/mL, 97 mg/L and 328 U/L respectively, as well as a CD4 T-cell count below 535 cells/µL, were the best cut-offs predicting severity since these parameters offered reliable areas under the curve. CONCLUSION: Age and sex together with selected laboratory parameters on admission can help us predict COVID-19 severity and, therefore, make clinical and resource management decisions. Demographic features associated with lockdown might affect the homogeneity of the data and the robustness of the results.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article